Drug intelligence / Profile preview

EVER-COVID19-M1

Development stage: Preclinical
Lead developer: Providence Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**EVER-COVID19-M1** is an investigational, Omicron-targeting bivalent messenger RNA COVID-19 booster vaccine candidate developed by Everest Medicines in collaboration with Providence Therapeutics. It is intended to induce protective immune responses against SARS-CoV-2, including Omicron-related viral variants. Everest reported rolling investigational new drug submissions for Phase 1 and Phase 2 studies and described the candidate as a potential basis for an emergency use authorization application in China.

Beyond the preview

Go deeper on EVER-COVID19-M1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVER-COVID19-M1.

Explore the full profile